ImmunityBio (IBRX) is trading lower as the market continues to digest regulatory and legal risk tied to Anktiva promotion. The FDA’s Office of Prescription Drug Promotion issued a warning letter dated March 13, 2026, flagging promotional communications involving a TV advertisement and a podcast, keeping a compliance overhang on the shares. The continued drumbeat of class-action deadline notices has also kept focus on headline risk rather than fundamentals.

FDA promotion-related actions can pressure biotech valuations because they raise uncertainty around commercialization practices, future marketing constraints, and management credibility. Even when product demand is improving, investors often discount the story until the company demonstrates clean, sustained compliance and reduced legal noise.

Near term, investors will look for evidence that the company’s remediation steps are sticking and that the regulatory issue is not expanding into broader commercial restrictions. Separately, the balance between strong early commercial traction and reputational/compliance risk will be key; the company recently disclosed preliminary Q1 2026 net product revenue of about $44.2 million and cash/marketable securities of about $381 million, but sentiment can remain fragile while the FDA warning and lawsuits stay in the spotlight.